Daily Management Review

Sanofi buys Belgium's Ablynx for € 3.9 billion


01/29/2018


The deal is another sign of M&A activity in the global biotech sector. Earlier, Ablynx rejected a purchase offer for € 2.6 billion from the Danish Novo Nordisk.



Sanofi will pay € 45 per share in cash to Ablynx with a 21.2% premium on the closing price on Friday.

The French company said that Ablynx would increase the long-term value for its shareholders. At the same time, the takeover is expected to have a neutral impact on Sanofi's earnings per share in 2018 and 2019.

Sanofi is already one of the major pharmaceutical partners of Ablynx after the deal in July 2017, devised to find new methods for the treatment of inflammatory diseases.

Having bought the Belgian company, Sanofi will have access to the most promising asset of Ablynx, the experimental drug Caplacizumab for the treatment of a rare bleeding disorder.

At the beginning of January 2018, the Danish pharmaceutical company Novo Nordisk made a proposal to acquire Ablynx, assessing the Belgian company at 2.6 billion euros (3.2 billion dollars) or 28 euros per share. The management of Ablynx felt that the company was undervalued.

The Sanofi offer represents a 48% premium to the offer of Novo Nordisk.

According to informed sources, after the rejection of Novo Nordisk's proposal, the Belgian company was expecting offers from Sanofi, Merck & Co. (outside the US and Canada - MSD) and Roche.

Ablynx’s most promising drug under development is Caplacizumab, intended for the treatment of acquired thrombotic thrombocytopenic purpura. In February 2017, the Belgian company sent an application for approval to the EMA. The filing of an application with the FDA is scheduled for the first half of 2018.

In addition, Ablynx is developing a drug for the treatment of respiratory syncytial virus ALX-017. Currently, the IIb stage of clinical trials is under way.

This month, there was a surge in multibillion-dollar deals in the field of biotechnology. For example, the American biotechnology company Celgene, specializing in drugs for the treatment of cancer and inflammatory diseases, announced the acquisition of its competitor Juno Therapeutics for $ 9 billion.

These transactions are caused by the need for large pharmaceutical companies to gain access to new promising medicines, developed by their smaller competitors.

Last week, Sanofi agreed to buy an American Bioverativ, which specializes in preparations for the treatment of hemophilia and other rare blood diseases, for $ 11.6 billion. This is Sanofi's largest transaction in seven years.

source: reuters.com






Science & Technology

Gene Editing of Human Embryo Could Find ‘Moral’ Grounds: UK’s Ethics Council

Baidu comes up with a self-driving bus

Developing countries are stepping up their own space programs

McAfee: Number of cybercrime attacks skyrocketed

RemoveDebris Mission To Clear Debris Of In Orbit Over Earth

British experts: Online gambling is dangerous

Vodafone Chooses ‘Highly Trafficked Urban’ Space As Its 5G Testing Grounds

Space To Become A Travel Destination By 2022

Dream Of Immortality Can Be Realised By 2045

Predicting A Patient’s Death Might Be Possible With Google’s Machine Learning Tool

World Politics

World & Politics

Germany asks to return € 4 thousand subsidies for the purchase of Tesla

Was Trump's visit to the UK the last straw?

Prime Minister May Could Alter Brexit Strategies, Said Ress-Mogg

Le Maire: The US refused to release France from anti-Iran sanctions

One Belt, One Road is facing difficulties around the world

Qatar to raise $ 4 billion to buy Eurofighter Typhoon jets

The UK sets to turn all cars zero-emission by 2030

Brexit Minister’s Resignation States May’s Brexit Policies Weakening The Country’s Stance